Zebinix eslicarbazepine acetate regulatory update

The Scottish Medicines Consortium approved the restricted use of Zebinix eslicarbazepine from Bial-Portela as an adjunct therapy for epilepsy in adults with partial-onset seizures with or without secondary generalization to only include those with highly refractory epilepsy that have been heavily pre-treated and remain uncontrolled with existing anti-epileptic drugs. The sodium channel blocker is approved in the EU as adjunctive therapy in adults with partial-onset seizures with or without secondary generalization. ...